301
Participants
Start Date
March 29, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
FE 999049
FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
GONAL-F
"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
Ferring Investigational Site, Shengyang
Ferring Investigational Site, Shanghai
Ferring Investigational Site, Shushan
Ferring Investigational Site, Tianjin
Ferring Investigational Site, Xiaobailou
Ferring Investigational Site, Nanchang
Ferring Investigational Site, Yuzhong
Ferring Investigational Site, Guangzhou
Ferring Investigational Site, Guangzhou
Ferring Investigational Site, Chengdu
Ferring Investigational Site, Zhengzhou
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY